Hims & Hers has reached an agreement with Novo Nordisk to collaborate on obesity treatments, marking a shift in strategy after recent tensions between the two companies over compounded weight-loss medications. The partnership will allow the telehealth platform to offer several FDA-approved drugs from Novo Nordisk while scaling back its promotion of compounded versions of similar treatments.
Under the arrangement, Hims & Hers will begin offering multiple dosages of the diabetes medication Ozempic as well as the obesity treatment Wegovy, including injectable and oral options, later this month. The company said it will continue to provide compounded semaglutide only on a limited basis through its platform and primarily for patients whose needs cannot be met by commercially available medications.
The agreement also resolves a legal dispute between the companies. Novo Nordisk will drop its lawsuit against Hims & Hers, which was filed after the telehealth provider announced plans to launch its own version of Novo’s new oral weight-loss drug. That proposal drew criticism from the drugmaker and scrutiny from regulators, ultimately prompting Hims & Hers to abandon the plan and rethink its approach.
As part of the revised strategy, Hims & Hers will stop advertising compounded semaglutide products on its platform and in marketing materials. Patients currently using those compounded treatments will be offered the option to transition to FDA-approved alternatives instead.
Executives say the move better aligns the company’s U.S. operations with its international model, which focuses on providing branded medications through partnerships with pharmaceutical manufacturers. The collaboration also reflects the growing demand for GLP-1 weight-loss drugs and the potential for digital health platforms to help expand access to these therapies at scale.
Company leaders say the partnership could support continued growth in the weight-loss segment, which executives have previously highlighted as a major opportunity for the business despite increased regulatory attention on compounded versions of GLP-1 drugs.
Click here to read the original news story.